In #FDAGuidance, “#nanomedicine” refers to a drug product that contains at least one component with a dimension in the size range of approximately 1 nanometer (nm) up to 100 nm. Focus of the guidance is on a risk-based regulatory strategy.
bioprocessonline.com/doc/fda…
Computer-aided 3D modeling enables quick assessment of previously undiscovered protein binding sites and helps scientists at @GainThera marry them to the correct therapeutic molecules. Find out how.
bioprocessonline.com/doc/com…
It is astonishing how often pharmas & biotechs commit similar or even the same #GMP mistakes — in (almost) always the same places. Here are two of the most common pitfalls to avoid: inadequate handling of deviations & inadequate handling of changes.
bioprocessonline.com/doc/fre…
You read, watch, listen, travel to conferences & events, and learn from all of it. But none of those is the leading information source for those seeking it. What medium do most biopharma leaders seek when it’s learning they’re yearning for? Conversation.
bioprocessonline.com/doc/whe…
In #FDAGuidance, “#nanomedicine” refers to a drug product that contains at least one component with a dimension in the size range of approximately 1 nanometer (nm) up to 100 nm. Focus of the guidance is on a risk-based regulatory strategy.
bioprocessonline.com/doc/fda…